Immunology & Inflammation Therapeutics
Climb Bio news and milestones
Climb Bio: 9 headlines on record, 2 headlines in the last 90 days. Its story counts 9 milestones.
Data updated Nov 17, 2026 · Back to the company report
9Headlines
2In 90 days
9Milestones
Headlines
Sep 32026
News · markets.businessinsider.com
29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 ...
Aug 62026
Press release · Nasdaq
--Climb Bio, Inc., a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the second quar…
May 72026
Press release · The Manila Times
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development
Apr 82026
Mar 25, 20252025
Press release · streetinsider.com
Jan 8, 20252025
News · Nasdaq
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025.
Dec 19, 20242024
News · YahooFinance
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 - Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech…
Sep 11, 20242024
Blog
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on Climb Bio.
Sources: the outlets named on each headline, each story once
Milestones
Nov 2026
Went public NASDAQ: CLYM
Jun 27, 2024
Jun 27, 2024
May 21, 2021
Oct 16, 2020
Oct 10, 2019
2018
Founded
Each milestone is dated by its source: registers, filings, the press
How to cite
Climb Bio, News. Alion, Nov 17, 2026. https://alion.io/company/climbbio/news
